Coya Therapeutics, Inc. is preparing to initiate an open-label extension (OLE) of its Phase 2/3 ALSTARS Trial, which evaluates COYA 302 for the treatment of amyotrophic lateral sclerosis (ALS). The announcement was made on October 14, 2026, and it signifies a crucial step in the company's ongoing efforts to address this challenging neurodegenerative disease.
The decision to launch the OLE comes in response to requests from ALSTARS investigators and study participants, allowing those who complete the initial 48-week treatment period to continue receiving COYA 302. This extension will enable the collection of longer-term efficacy and safety data, which is vital for understanding the drug's impact on ALS.
Background
Coya Therapeutics, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. The company trades on the Nasdaq under the ticker symbol COYA. Its recent filings indicate a commitment to advancing clinical trials and product development.
What the Filing Says
The filing states, "On October 14, 2026, Coya Therapeutics, Inc. issued a press release announcing plans to initiate an open-label extension of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of ALS." This OLE is expected to begin in November 2026, coinciding with the completion of the first cohort's treatment period.
Additionally, the company plans to prioritize resources toward the ongoing clinical development of COYA 302 in ALS, which may delay the anticipated Phase 2 clinical trial for frontotemporal dementia (FTD) to 2027.
Impact
This development may significantly affect patients enrolled in the ALSTARS Trial, as they will have the opportunity to continue treatment with COYA 302. The extended trial could also influence the broader pharmaceutical industry, particularly companies focused on neurodegenerative diseases, as they observe the outcomes and data collected from this OLE.
What's Next
The filing does not say what happens next beyond the initiation of the OLE. However, the company’s ongoing commitment to its clinical trials suggests that further updates will follow as they continue to gather data and evaluate the efficacy of COYA 302.